1 Guidance
|
This guidance should be read in conjunction with NICE technology appraisal guidance 86 (TA86) 'Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours'. This guidance updates recommendation 1.5 of TA86. All other recommendations in TA86 still stand. |
1.1 Imatinib at 600 or 800 mg/day is not recommended for people with unresectable and/or metastatic gastrointestinal stromal tumours whose disease has progressed after treatment with 400 mg/day imatinib.
1.2 People who are currently receiving 600 or 800 mg/day imatinib for unresectable and/or metastatic gastrointestinal stromal tumours should have the option to continue therapy until they and their clinicians consider it appropriate to stop.